KR20200115610A - 스피로-락탐 nmda 수용체 조정제 및 그의 용도 - Google Patents

스피로-락탐 nmda 수용체 조정제 및 그의 용도 Download PDF

Info

Publication number
KR20200115610A
KR20200115610A KR1020207024903A KR20207024903A KR20200115610A KR 20200115610 A KR20200115610 A KR 20200115610A KR 1020207024903 A KR1020207024903 A KR 1020207024903A KR 20207024903 A KR20207024903 A KR 20207024903A KR 20200115610 A KR20200115610 A KR 20200115610A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
independently selected
group
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020207024903A
Other languages
English (en)
Korean (ko)
Inventor
엠. 아민 관
Original Assignee
앱티닉스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 앱티닉스 인크. filed Critical 앱티닉스 인크.
Publication of KR20200115610A publication Critical patent/KR20200115610A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020207024903A 2018-01-31 2019-01-31 스피로-락탐 nmda 수용체 조정제 및 그의 용도 Withdrawn KR20200115610A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862624218P 2018-01-31 2018-01-31
US62/624,218 2018-01-31
US201862718107P 2018-08-13 2018-08-13
US62/718,107 2018-08-13
PCT/US2019/016098 WO2019152678A1 (en) 2018-01-31 2019-01-31 Spiro-lactam nmda receptor modulators and uses thereof

Publications (1)

Publication Number Publication Date
KR20200115610A true KR20200115610A (ko) 2020-10-07

Family

ID=65494516

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207024903A Withdrawn KR20200115610A (ko) 2018-01-31 2019-01-31 스피로-락탐 nmda 수용체 조정제 및 그의 용도

Country Status (15)

Country Link
US (1) US20210047324A1 (https=)
EP (1) EP3746442A1 (https=)
JP (2) JP2021512109A (https=)
KR (1) KR20200115610A (https=)
CN (1) CN112218866A (https=)
AU (1) AU2019215049A1 (https=)
BR (1) BR112020015666A2 (https=)
CA (1) CA3089559A1 (https=)
CL (1) CL2020001990A1 (https=)
IL (1) IL276330A (https=)
MX (1) MX2020008106A (https=)
PE (1) PE20211455A1 (https=)
PH (1) PH12020551140A1 (https=)
SG (1) SG11202007251XA (https=)
WO (1) WO2019152678A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA032649B1 (ru) 2013-01-29 2019-06-28 Аптиникс Инк. Спиролактамные модуляторы nmda-рецептора и их применение
MX385336B (es) 2016-08-01 2025-03-18 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos.
WO2018026782A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
SG10202101055VA (en) 2016-08-01 2021-03-30 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
JP2019527232A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタムnmda修飾因子及びこれを用いた方法
CN112204031B (zh) 2018-01-31 2024-05-24 元羿生物科技(香港)有限公司 螺-内酰胺nmda受体调节剂及其用途
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
WO2019222677A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
GEP20237548B (en) 2018-07-05 2023-10-10 Incyte Corp Fused pyrazine derivatives as a2a /a2b inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
WO2024054919A1 (en) * 2022-09-08 2024-03-14 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda receptor modulators and uses thereof
US20250115551A1 (en) * 2023-10-03 2025-04-10 Revolution Medicines, Inc. Synthesis of ras inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011003015A (es) * 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
CN105037492A (zh) * 2010-02-11 2015-11-11 西北大学 二级结构稳定化的nmda受体调节剂及其用途
CN102267995A (zh) * 2010-06-04 2011-12-07 艾琪康医药科技(上海)有限公司 一种制备二氮杂螺环化合物的方法
EA032649B1 (ru) * 2013-01-29 2019-06-28 Аптиникс Инк. Спиролактамные модуляторы nmda-рецептора и их применение
KR20150110586A (ko) * 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
SG11201505862TA (en) * 2013-01-29 2015-08-28 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
SG11201505942YA (en) * 2013-01-29 2015-08-28 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
KR20150110787A (ko) * 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
HUE049481T2 (hu) * 2015-04-03 2020-09-28 Recurium Ip Holdings Llc Spirociklusos vegyületek
WO2017201285A1 (en) * 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
BR112018073663A2 (pt) * 2016-05-19 2019-04-30 Aptinyx Inc. moduladores de receptores nmda spiro-lactâmicos e seus usos
SG10202101055VA (en) * 2016-08-01 2021-03-30 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
AR110988A1 (es) * 2017-02-21 2019-05-22 Sanofi Sa Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados
JP2022092387A (ja) * 2020-12-10 2022-06-22 キヤノン株式会社 画像形成装置

Also Published As

Publication number Publication date
AU2019215049A1 (en) 2020-09-17
IL276330A (en) 2020-09-30
EP3746442A1 (en) 2020-12-09
PH12020551140A1 (en) 2021-05-31
CN112218866A (zh) 2021-01-12
BR112020015666A2 (pt) 2021-02-23
WO2019152678A1 (en) 2019-08-08
CA3089559A1 (en) 2019-08-08
SG11202007251XA (en) 2020-08-28
PE20211455A1 (es) 2021-08-05
MX2020008106A (es) 2020-09-25
CL2020001990A1 (es) 2021-03-26
JP2024019396A (ja) 2024-02-09
US20210047324A1 (en) 2021-02-18
JP2021512109A (ja) 2021-05-13

Similar Documents

Publication Publication Date Title
KR20200115610A (ko) 스피로-락탐 nmda 수용체 조정제 및 그의 용도
US10316041B2 (en) Spiro-lactam NMDA receptor modulators and uses thereof
US10273239B2 (en) Spiro-lactam NMDA receptor modulators and uses thereof
US11427585B2 (en) Spiro-lactam NMDA modulators and methods of using same
US10253032B2 (en) Spiro-lactam NMDA receptor modulators and uses thereof
EP3514158B1 (en) Spiro-lactam nmda receptor modulators and uses thereof
EP3490994B1 (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
KR102465757B1 (ko) 스피로-락탐 nmda 수용체 조정제 및 그의 용도
KR20200115611A (ko) 스피로-락탐 nmda 수용체 조정제 및 그의 용도
WO2019152696A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2024054919A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2019152681A1 (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
NZ709872B2 (en) Spiro-lactam nmda receptor modulators and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202